Plasma proteomic analysis of pancreatic cancer by 2-dimensional gel electrophoresis

Pancreas

Volumn 34, Issue 3, 2007, Pages 310-317

  Deng, Ruixue ^a   Lu, Zhaohui ^a   Chen, Yuanjia ^a   Zhou, Lu ^a   Lu, Xinghua ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

2 dimensional gel electrophoresis; Chronic pancreatitis; Pancreatic cancer; Plasma; Protein profile

Indexed keywords

ALPHA 1 ANTITRYPSIN; ALPHA2 GLYCOPROTEIN; HAPTOGLOBIN; IMMUNOGLOBULIN J CHAIN; PLASMA PROTEIN; TRYPSIN INHIBITOR;

ADULT; AGED; AMINO ACID SEQUENCE; ARTICLE; BLOOD SAMPLING; CANCER SURGERY; CHRONIC PANCREATITIS; CLINICAL ARTICLE; FEMALE; HUMAN; MALE; PANCREAS CANCER; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEOMICS; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION;

ADULT; BLOOD PROTEINS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROTEOMICS; REFERENCE VALUES;

EID: 34247123637     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e31802f2483     Document Type: Article

References (46)

1. National Cancer Institute. Annual Cancer Statistics Review 1973-1988 (NIH publication no. 91-2789). Bethesda, MD: Department of Health and Human Services; 1991.
2. Wang L, Yang GH, Lu XH, et al. Pancreatic cancer mortality in China (1991-2000). World J Gastroenterol. 2003;9:1819-1823.
3. Parker SL, Tong T, Bolden S, et al. Cancer statistics 1996. CA Cancer J Clin. 1996;46:5-27.
4. Rosty C, Goggins M. Early detection of pancreatic carcinoma. Hematol Oncol Clin North Am. 2002;16:37-52.
5. Rosty C, Christa L, Kuzdzal S, et al. Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res. 2002;62:1868-1875.
6. Koopmann J, Zhang Z, White N, et al. Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res. 2004;10:860-868.
7. Bhattacharyya S, Siegel ER, Petersen GM, et al. Diagnosis of pancreatic cancer using serum proteomic profiling. Neoplasia. 2004;6:674-686.
8. Koomen JM, Shih LN, Coombes KR, et al. Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins. Clin Cancer Res. 2005;11:1110-1118.
9. Sobin LH, Wittekind C, International Union Against Cancer (UICC), eds. TNM Classification of Malignant Tumors. 5th ed. New York, NY: Wiley-Liss; 1997:227.
10. Ahmed N, Barker G, Oliva KT, et al. Proteomic-based identification of haptoglobin-1 precursor as a novel circulating biomarker of ovarian cancer. Br J Cancer. 2004;91:129-140.
11. Mateos-Caceres PJ, Garcia-Mendez A, Farre AL, et al. Proteomic analysis of plasma from patients during an acute coronary syndrome. J Am Coll Cardiol. 2004;44:1578-1583.
12. Chen JH, Chang YW, Yao CW, et al. Plasma proteome of severe acute respiratory syndrome analyzed by two-dimensional gel electrophoresis and mass spectrometry. Proc Natl Acad Sci U S A. 2004;101:17039-17044.
13. Joo WA, Kang MJ, Son WK, et al. Monitoring protein expression by proteomics: human plasma exposed to benzene. Proteomics. 2003;3:2402-2411.
14. Langlois MR, Delanghe JR. Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem. 1996;42:1589-1600.
15. Zhao H, Zhang G, Duan Y, et al. Haptoglobin types in Chinese ethnic groups. Hum Hered. 1993;43:131-133.
16. Tsamantanis C, Delinassios JG, Kottaridis S, et al. Haptoglobin types in breast carcinoma. Hum Hered. 1980;30:44-47.
17. Bartel U, Elling D, Geserick G. Distribution of haptaglobin phenotypes in gynacologic tumors. Zentralbl Gynäkol. 1985;107:1492-1495.
18. Jayanthi M, Habibullah CM, Ishaq M, et al. Distribution of haptoglobin phenotypes in oesophageal and gastric cancer. J Med Genet. 1989;26:172-173.
19. Diamandis EP. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst. 2004;96:353-356.
20. Oh SK, Very DL, Walker J, et al. An analogy between fetal haptoglobin and a potent immunosuppressant in cancer. Cancer Res. 1987;47:5120-5126.
21. Oh SK, Kim SH, Walker JE. Interference with immune response at the level of generating effector cells by tumor-associated haptoglobin. J Natl Cancer Inst. 1990;82:934-940.
22. Woong-Shick A, Sung-Pil P, Su-Mi B, et al. Identification of hemoglobin-alpha and -beta subunits as potential serum biomarkers for the diagnosis and prognosis of ovarian cancer. Cancer Sci. 2005;96:197-201.
23. Zhang R, Barker L, Pinchev D, et al. Mining biomarkers in human sera using proteomic tools. Proteomics. 2004;4:244-256.
24. Kristiansen M, Graversen JH, Jacobsen C, et al. Identification of the hemoglobin scavenger receptor. Nature. 2001;409:198-201.
25. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860-867.
26. Basso D, Fabris C, Del Favero G, et al. Acute phase proteins in chronic pancreatic disease. Acta Gastroenterol Belg. 1989;52:399-405.
27. Haber PS, Wilson JS, McGarity BH, et al. Alpha 1 antitrypsin phenotypes and alcoholic pancreatitis. Gut. 1991;32:945-948.
28. Lankisch CP, Koop H, Winckler K, et al. α1AT in pancreatic disease. Digestion. 1978;18:138-140.
29. Tountas Y, Sparos L, Theodoropoulos CH, et al. α1AT and cancer of the pancreas. Digestion. 1985;31:37-40.
30. 1AT levels and phenotypes and hepatitis B serology in liver cancer. Br J Cancer. 1984;49:567-570.
31. Thompson DN, Haddow JE, Smith DE, et al. Elevated serum acute phase protein levels as predictors of disseminated breast cancer. Cancer. 1983;51:2100-2104.
32. 1AT and survival in pancreatic cancer. Int J Cancer. 1990;45:685-686.
33. Koshiland ME. The coming of age of the immunoglobulin J chain. Annu Rev Immunol. 1985;3:425-453.
34. Bank S, Novis BH, Dowdle E, et al. Serum immunoglobulins in calcific pancreatitis. Gut. 1973;14:723-725.
35. Frulloni L, Negri M, Brunelli S, et al. High serum levels of secretory immunoglobulin A in chronic pancreatitis. Dig Liver Dis. 2000;32:329-334.
36. Emmrich J, Seyfarth M, Conradi P, et al. Secretory immunoglobulin A in pancreatic juice and pancreatic tissue of patients with chronic pancreatitis. Gut. 1998;42:436-441.
37. 2 -glycoprotein of human serum. Proc Natl Acad Sci U S A. 1985;82:1906-1910.
38. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448-454.
39. Doustjalali SR, Yusof R, Yip CH, et al. Aberrant expression of acute-phase reactant proteins in sera and breast lesions of patients with malignant and benign breast tumors. Electrophoresis. 2004;25:2392-2401.
40. Zhao R, Ji JG, Tong YP, et al. Use of serological proteomic methods to find biomarkers associated with breast cancer. Proteomics. 2003;3:433-439.
41. Ye B, Cramer DW, Skates SJ, et al. Haptoglobin-α subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. Clin Cancer Res. 2003;9:2904-2911.
42. Le L, Chi K, Tyldesley S, et al. Identification of serum amyloid a as a biomarker to distinguish prostate caner patients with bone lesions. Clin Chem. 2005;51:695-707.
43. Cho WC, Yip TT, Yip C, et al. Identification of serum amyloid A protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling. Clin Cancer Res. 2004;10:43-52.
44. Diamandis EP. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool. Mol Cell Proteomics. 2004;3:367-378.
45. Anderson NL, Anderson NG. The human plasma proteome. Mol Cell Proteomics. 2002;1:845-867.
46. Quero C, Colome N, Prieto MR, et al. Determination of protein markers in human serum: analysis of protein expression in toxic oil syndrome studies. Proteomics. 2004;4:303-315.